Form 4: Intellia Therapeutics Director Muna Bhanji Sells 265 Shares Under 10b5-1 Plan

Director Muna Bhanji of Intellia Therapeutics sold 265 shares of common stock on April 29, 2025, at a price of $8.5 per share, according to a Form 4 filing with the SEC.

Summary

• Muna Bhanji, a director at Intellia Therapeutics, Inc. (NTLA), reported a transaction involving the sale of common stock.
• On April 29, 2025, Bhanji sold 265 shares of Intellia Therapeutics common stock at a price of $8.5 per share.
• The sale was executed automatically under a pre-arranged 10b5-1 trading plan adopted on September 27, 2024.
• Following the transaction, Bhanji directly owns 19,203 shares of Intellia Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to a pre-planned stock sale by a company director. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

Sales by insiders are a normal part of corporate governance. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Muna Bhanji, Form 4, SEC Filing, Stock Sale, 10b5-1 Trading Plan, Director, Common Stock